The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study.
M. G. del Carmen
Research Funding - Centocor Ortho Biotech
J. P. Micha
Research Funding - Centocor Ortho Biotech
L. A. Small
Research Funding - Centocor Ortho Biotech
D. G. Street
Research Funding - Centocor Ortho Biotech
A. Londhe
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Research Funding - Centocor Ortho Biotech
T. McGowan
Employment or Leadership Position - Centocor Ortho Biotech
Stock Ownership - Johnson & Johnson
Research Funding - Centocor Ortho Biotech